Recursion Pharmaceuticals, Inc. - Class A
News
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $12.67 Consensus Target Price from Brokerages
Zolmax Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been assigned an average rating of "Hold" from the six analysts that are currently covering the company, MarketBeat...\n more…
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.6% Following Insider Selling
Ticker Report Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares dropped 0.6% during mid-day trading on Friday after an insider sold shares in the company. The stock traded as low as $6.10 and...\n more…
Needham & Company LLC Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $11.00
Ticker Report Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) had its price objective dropped by research analysts at Needham Company LLC from $16.00 to $11.00 in a research note issued on...\n more…
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $12.67 Consensus Price Target from Analysts
Ticker Report Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been given an average recommendation of "Hold" by the six brokerages that are presently covering the firm, Marketbeat Ratings...\n more…
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $45,360.00 in Stock
Ticker Report Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 6,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an...\n more…